• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ANASTROZOLE Drug Record

  • Summary
  • Interactions
  • Claims
  • ANASTROZOLE chembl:CHEMBL1399 ApprovedAntineoplastic

    Alternate Names:

    ANASTROZOLE
    ARIMIDEX
    NASTROSA
    ICI-D1033
    ZD-1033
    ANASTROZOL
    ALPHA,ALPHA,ALPHA',ALPHA'-TETRAMETHYL-5-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-M-BENZENEDIACETONITRILE
    ARIMIDEX®
    ZD1033
    drugbank:01217
    rxcui:84857
    chemidplus:120511-73-1
    chembl:CHEMBL1399
    pubchem.compound:2187

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    Year of Approval 1995
    Drug Class antineoplastic agents
    (6 More Sources)

    Publications:

    Mauras et al., 2009, Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia., J. Clin. Endocrinol. Metab.
    Gangadhara et al., 2009, Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women., Ther Clin Risk Manag
    Nabholtz, 2006, Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention., Oncology
    Milani et al., 2009, Anastrozole Use in Early Stage Breast Cancer of Post-Menopausal Women., Clin Med Ther
    Santen et al., 2009, History of aromatase: saga of an important biological mediator and therapeutic target., Endocr. Rev.
    Cuzick, 2005, Anastrozole., Drugs Today
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rugo, 2008, The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors., Ann. Oncol.
    Jakesz et al., 2007, Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a., J. Natl. Cancer Inst.
    Wang L et al., 2010, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors., Cancer Res
    Powlin et al., 1998, Ex vivo and in vitro testis and ovary explants: utility for identifying steroid biosynthesis inhibitors and comparison to a Tier I screening battery., Toxicol. Sci.
    O'Connor et al., 1998, An ongoing validation of a Tier I screening battery for detecting endocrine-active compounds (EACs)., Toxicol. Sci.
    Miller WR, 2003, Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer., Semin Oncol
    Kelly CM et al., 2010, Anastrozole., Expert Opin Drug Saf
    Buzdar AU et al., 2002, An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane., Cancer
    Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.
    Ferrari et al., 2002, Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients., J. Steroid Biochem. Mol. Biol.
    Edavana VK et al., 2013, Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics., Drug Metab Dispos
    Liu M et al., 2014, Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics., Mol Endocrinol
    Gala K et al., 2018, KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function., Oncogene
  • ANASTROZOLE   KMT2C

    Interaction Score: 3.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29755131


    Sources:
    CIViC

  • ANASTROZOLE   CYP19A1

    Interaction Score: 2.94

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cytochrome P450 19A1 inhibitor
    Direct Interaction yes
    Trial Name anastrozole,Arimidex

    PMIDs:
    19470631 19753124 16439860 19794821 19389994 16034487 11752352 17693420 18073378 20048079 9928669 9928668 14513432 20923259 12404296


    Sources:
    TdgClinicalTrial ChemblInteractions NCI TEND PharmGKB TTD

  • ANASTROZOLE   TNFSF11

    Interaction Score: 1.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ANASTROZOLE   TNFRSF11B

    Interaction Score: 0.95

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ANASTROZOLE   UGT1A4

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23371966


    Sources:
    PharmGKB

  • ANASTROZOLE   IGF2

    Interaction Score: 0.68

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11983488


    Sources:
    NCI

  • ANASTROZOLE   CYP1B1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18256205


    Sources:
    NCI

  • ANASTROZOLE   PGR

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers PharmGKB FDA

  • ANASTROZOLE   TUBB1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25148458


    Sources:
    PharmGKB

  • ANASTROZOLE   MAP4K4

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ANASTROZOLE   ESR2

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ANASTROZOLE   ESR1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers PharmGKB FDA

  • ANASTROZOLE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: ANASTROZOLE

    • Version: 01-August-2011

    Alternate Names:
    ANASTROZOLE Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 1995

    Publications:

  • TdgClinicalTrial: ANASTROZOLE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: ANASTROZOLE

    • Version: 14-September-2017

    Alternate Names:
    C1607 NCI drug code

    Drug Info:

    Publications:
    Ferrari et al., 2002, Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients., J. Steroid Biochem. Mol. Biol.
    Rahman et al., 2008, CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma., Drug Metab. Dispos.
    Powlin et al., 1998, Ex vivo and in vitro testis and ovary explants: utility for identifying steroid biosynthesis inhibitors and comparison to a Tier I screening battery., Toxicol. Sci.

  • PharmGKB: anastrozole

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Wang L et al., 2010, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors., Cancer Res
    Edavana VK et al., 2013, Potential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomics., Drug Metab Dispos
    Liu M et al., 2014, Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics., Mol Endocrinol

  • CIViC: ANASTROZOLE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Gala K et al., 2018, KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function., Oncogene

  • TTD: Anastrozole

    • Version: 2020.06.01

    Alternate Names:
    D0W0BF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1399

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1399

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: ANASTROZOLE

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Anastrozole

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21